According to the research report titled ‘United States Vaccines Market Size, Top 45 Vaccines Brand In-depth Analysis, Trends, Shares, Insights, and Forecasts to 2027’, available with MarketStudyReport, United States vaccines market is slated to be worth USD 30 billion by the end of the forecast period 2021-2027.
 

Factors such as rise in prevalence of infectious diseases, supportive government policies for vaccine development, ongoing R&D activities, and increasing focus on immunization are driving the United States vaccines market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3950418/
 

Notably, the research report comprehensively analyzes the industry to offer the most up-to-date data on the current scenario as well as the future outlook of this business vertical. Furthermore, historical market data from 2018-2020 is dissected to forecast the growth trajectory over 2021-2027.
 

The document studies the market based on product type and lists the 45 vaccine brands prevailing in the market scenario namely, Daptacel, Kinrix, Quadracel, Vaxelis, Pentacel, Vaqta, IPOL, Twinrix, Havrix, Recombivax HB, ActHIB, Engerix B, PedvaxHIB, Tenivac, Hiberix, FluMist Quadrivalent, MenQuadfi, Imovax, Gardasil 9, Fluzone Quadrivalent, Prevnar 13, TDVAX, Fluad, Flucelvax Quadrivalent, and Afluria Quadrivalent among others.
 

It also defines the growth rate and market share captured by each of these brands and elaborates on the pricing analysis, trends, & insights, while highlighting the regulatory framework of the United States vaccines market.
 

Speaking of competitive landscape, companies such as Grifols S.A., Dynavax Technologies Corp., AstraZeneca plc, Seqirus U.K. Ltd., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline (GSK) plc, and Sanofi Pasteur are influencing the United States vaccines market dynamics. The report analyses the detailed profiles of these companies while also presenting business overview, vaccine portfolios, and a list of promising vaccines in various stages of clinical development.
 

Proceeding further, the report tracks the competitive strategies being adopted by leading players such as partnership deals, collaborations, exclusive & licensing agreements, new vaccine development, distribution deals, and R&D activities.